Shenzhen Kangtai Biological Products Co., Ltd.
Announcement on the Board of Directors' Proposal to Lower the Conversion Price of "Kangtai Convert 2" and Commitment Not to Propose Further Downward Adjustments in the Future
The Company and all members of the Board of Directors guarantee the content of the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Shenzhen Kangtai Biological Products Co., Ltd. (hereinafter referred to as the "Company") held its eleventh meeting of the eighth Board of Directors on August 5, 2026, and deliberated and passed the "Proposal on the Board of Directors' Proposal to Lower the Conversion Price of 'Kangtai Convert 2' and Commitment Not to Propose Further Downward Adjustments in the Future." This proposal needs to be submitted to the Company's first extraordinary general meeting of shareholders in 2026 for deliberation. The relevant matters are hereby announced as follows:
I. Basic Information on the Issuance and Listing of Convertible Bonds
(I) Convertible Bond Issuance
With the approval of the China Securities Regulatory Commission's "CSRC License (2021) No. 1873," the Company issued 20,000,000 convertible bonds to unspecified targets on July 15, 2021. Each bond has a face value of RMB 100, and the total raised capital was RMB 2,000,000,000. After deducting underwriting fees, sponsorship fees, and other expenses of RMB 10,340,000 (including tax), the net raised capital was RMB 1,989,660,000. The capital raised has been verified by Xinyonghe Certified Public Accountants (Special General Partnership) and a capital verification report with the number XYZH/2021SZAA40430 has been issued.
(II) Convertible Bond Listing
With the approval of the Shenzhen Stock Exchange, the Company's convertible bonds were listed and traded on the Shenzhen Stock Exchange starting from August 5, 2021. The bond's short name is "Kangtai Convert 2," and the bond code is "123119."